| CENTER ID: | BupsE.18028.a |
| ORGANISM: | Burkholderia pseudomallei K96243 |
| ASSOCIATED DISEASE: | Melioidosis |
| CURRENT STATUS: | in PDB |
| COMMUNITY REQUEST: | True |
| NIH RISK GROUP: | 3 |
| SELECT AGENT: | True |
| NIH PRIORITY pathogens category: |
IIIB |
| CENTER REFERENCE ID |
DOMAIN/REGION DESCRIPTION |
INFO | AA START |
AA STOP |
ORDER MATERIAL |
|---|---|---|---|---|---|
| BupsE.18028.a.A1.GE34311 | full length | 1 | 208 |
| CENTER REFERENCE ID |
DOMAIN/REGION DESCRIPTION |
INFO | AA START |
AA STOP |
ORDER MATERIAL |
|---|---|---|---|---|---|
| BupsE.18028.a.A1.PS01510 | full length | 1 | 208 |
| TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases | |
| J Totzke, SA Scarneo, KW Yang- Open, 2020 - royalsocietypublishing.org | |
| cited by: | 53 others |
| PDB: 4JGB | |
| Targeting Transforming Growth Factor Beta-Activated Kinase 1 as a Therapeutic | |
| J Totzke - 2017 - dukespace.lib.duke.edu | |
| PDB: 4JGB |
| RESOURCE | REFERENCE ID |
|---|---|
| BV-BRC: | fig|272560.6.peg.1413 |
| RefSeq: | YP_107894.1 |
| UniProt: | Q63VH2 |
| HARVESTED ON: | 1/10/2012 |
| SEQUENCED ON: | 1/13/2012 |
| EXPECTED MW: | 23kDa |
| OBSERVED MW: | 25kDa |
| ANTIBIOTIC MARKER: | ampicillin |
| COUNT OF EXPRESSION COLONIES: | Too many to count (100+) |
| TOTAL EXPRESSION LEVEL: | Low Expression |
| SOLUBLE EXPRESSION LEVEL | Moderate Expression |
| EXPRESSION HOST: | data unavailable |
| SEQUENCING RESULT: | pass |
| PERCENT IDENTITY: | 100 |
| PERCENT COVERAGE: | 100 |
| PURIFICATION DATe: | 5/22/2012 |
| CONCENTRATION: | 46.2mg/ml |
| OBSERVED MW: | 25kDa |
| EXPRESSION LEVEL: | Low Expression |
| PROTEIN PURIFICATION BUFFER: | 20 mM HEPES, pH 7.0, 300 mM NaCl, 5% glycerol and 1 mM TCEP |
| EXPRESSION HOST: | data unavailable |
| VIAL COUNT (approx.): | 9 |
| VIAL VOLUME: | 110µl |
| PERCENT IDENTITY: | 100 |
| PERCENT COVERAGE: | 100 |